Verified, source-grounded records

Verified studies for Tesamorelin

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Verified study counts

62 current verified studies.

Human research: 0
In vitro: 0
In vivo/preclinical: 0
Review/meta-analysis: 0
Other: 0

Current verified studies

Study type: Human research · Status: Citation only

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Chemical sequence-1 Receptor Agonists.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Obesity research & clinical practice · 2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation only

<b>TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS</b>

INTERNATIONAL BLEST SCIENTIFIC · 2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vivo/preclinical · Status: Citation only

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

TESAMORELIN AMONG GROWTH HORMONE SECRETAGOGUE CHEMICAL SEQUENCES: A COMPARATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, VISCERAL FAT REDUCTION, ENDOCRINE SELECTIVITY, AND SAFETY

2026

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis

2025

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

The Journal of infectious diseases · 2025

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

AIDS (London, England) · 2024

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

2023

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Journal of clinical and translational science · 2023

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Causes and outcomes of hepatic fibrosis in persons living with HIV.

Current opinion in HIV and AIDS · 2022

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Scientific reports · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Tesamorelin improves fat quality independent of changes in fat quantity.

AIDS (London, England) · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: In vitro · Status: Citation only

Advances in the detection of growth hormone releasing hormone synthetic analogs.

Drug testing and analysis · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial

2020

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight · 2020

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.

Study type: Human research · Status: Citation only

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

UNC Libraries · 2020

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

Tesamorelin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation only. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.